Anne M Butler1, J Bradley Layton2, Vikas R Dharnidharka3, John M Sahrmann4, Marissa J Seamans5, David J Weber6, Leah J McGrath7. 1. Division of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO; Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, MO. Electronic address: anne.butler@wustl.edu. 2. RTI Health Solutions, Research Triangle Park, NC. 3. Division of Pediatric Nephrology, Hypertension and Pheresis, Department of Pediatrics, Washington University School of Medicine, St. Louis, MO. 4. Division of Infectious Diseases, Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO. 5. Department of Mental Health, The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 6. Division of Infectious Diseases, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC. 7. NoviSci, Durham, NC.
Abstract
RATIONALE & OBJECTIVE: Studies of patients on maintenance dialysis therapy suggest that standard-dose influenza vaccine (SDV) may not prevent influenza-related outcomes. Little is known about the comparative effectiveness of SDV versus high-dose influenza vaccine (HDV) in this population. STUDY DESIGN: Cohort study using data from the US Renal Data System. SETTING & PARTICIPANTS: 507,552 adults undergoing in-center maintenance hemodialysis between the 2010 to 2011 and 2014 to 2015 influenza seasons. EXPOSURES: SDV and HDV. OUTCOMES: All-cause mortality, hospitalization due to influenza or pneumonia, and influenza-like illness during the influenza season. ANALYTIC APPROACH: Patients were eligible for inclusion in multiple yearly cohorts; thus, our unit of analysis was the influenza patient-season. To examine the relationship between vaccine dose and effectiveness outcomes, we estimated risk differences and risk ratios using propensity score weighting of Kaplan-Meier functions, accounting for a wide range of patient- and facility-level characteristics. For nonmortality outcomes, we used competing-risk methods to account for the high mortality rate in the dialysis population. RESULTS: Within 225,215 influenza patient-seasons among adults 65 years and older, 97.4% received SDV and 2.6% received HDV. We observed similar risk estimates for HDV and SDV recipients for mortality (risk difference, -0.08%; 95% CI, -0.85% to 0.80%), hospitalization due to influenza or pneumonia (risk difference, 0.15%; 95% CI, -0.69% to 0.93%), and influenza-like illness (risk difference, 0.00%; 95% CI, -1.50% to 1.08%). Our findings were similar among adults younger than 65 years, as well as within other subgroups defined by influenza season, age group, dialysis vintage, month of influenza vaccination, and vaccine valence. LIMITATIONS: Residual confounding and outcome misclassification. CONCLUSIONS: The HDV does not appear to provide additional protection beyond the SDV against all-cause mortality or influenza-related outcomes for adults undergoing hemodialysis. The additional cost and side effects associated with HDV should be considered when offering this vaccine. Future studies of HDV and other influenza vaccine strategies are warranted.
RATIONALE & OBJECTIVE: Studies of patients on maintenance dialysis therapy suggest that standard-dose influenza vaccine (SDV) may not prevent influenza-related outcomes. Little is known about the comparative effectiveness of SDV versus high-dose influenza vaccine (HDV) in this population. STUDY DESIGN: Cohort study using data from the US Renal Data System. SETTING & PARTICIPANTS: 507,552 adults undergoing in-center maintenance hemodialysis between the 2010 to 2011 and 2014 to 2015 influenza seasons. EXPOSURES: SDV and HDV. OUTCOMES: All-cause mortality, hospitalization due to influenza or pneumonia, and influenza-like illness during the influenza season. ANALYTIC APPROACH: Patients were eligible for inclusion in multiple yearly cohorts; thus, our unit of analysis was the influenzapatient-season. To examine the relationship between vaccine dose and effectiveness outcomes, we estimated risk differences and risk ratios using propensity score weighting of Kaplan-Meier functions, accounting for a wide range of patient- and facility-level characteristics. For nonmortality outcomes, we used competing-risk methods to account for the high mortality rate in the dialysis population. RESULTS: Within 225,215 influenzapatient-seasons among adults 65 years and older, 97.4% received SDV and 2.6% received HDV. We observed similar risk estimates for HDV and SDV recipients for mortality (risk difference, -0.08%; 95% CI, -0.85% to 0.80%), hospitalization due to influenza or pneumonia (risk difference, 0.15%; 95% CI, -0.69% to 0.93%), and influenza-like illness (risk difference, 0.00%; 95% CI, -1.50% to 1.08%). Our findings were similar among adults younger than 65 years, as well as within other subgroups defined by influenza season, age group, dialysis vintage, month of influenza vaccination, and vaccine valence. LIMITATIONS: Residual confounding and outcome misclassification. CONCLUSIONS: The HDV does not appear to provide additional protection beyond the SDV against all-cause mortality or influenza-related outcomes for adults undergoing hemodialysis. The additional cost and side effects associated with HDV should be considered when offering this vaccine. Future studies of HDV and other influenza vaccine strategies are warranted.
Authors: Carlos A DiazGranados; Andrew J Dunning; Emilia Jordanov; Victoria Landolfi; Martine Denis; H Keipp Talbot Journal: Vaccine Date: 2012-12-20 Impact factor: 3.641
Authors: Carlos A DiazGranados; Andrew J Dunning; Murray Kimmel; Daniel Kirby; John Treanor; Avi Collins; Richard Pollak; Janet Christoff; John Earl; Victoria Landolfi; Earl Martin; Sanjay Gurunathan; Richard Nathan; David P Greenberg; Nadia G Tornieporth; Michael D Decker; H Keipp Talbot Journal: N Engl J Med Date: 2014-08-14 Impact factor: 91.245
Authors: Leah J McGrath; Abhijit V Kshirsagar; Stephen R Cole; Lily Wang; David J Weber; Til Stürmer; M Alan Brookhart Journal: Arch Intern Med Date: 2012-04-09
Authors: Yinong Young-Xu; Robertus Van Aalst; Salaheddin M Mahmud; Kenneth J Rothman; Julia Thornton Snider; Daniel Westreich; Vincent Mor; Stefan Gravenstein; Jason K H Lee; Edward W Thommes; Michael D Decker; Ayman Chit Journal: J Infect Dis Date: 2018-05-05 Impact factor: 5.226
Authors: J Bradley Layton; Leah J McGrath; John M Sahrmann; Yinjiao Ma; Vikas R Dharnidharka; Caroline O'Neil; David J Weber; Anne M Butler Journal: Vaccine Date: 2020-06-19 Impact factor: 3.641